RO6958688

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Carcinoma, Non-Small-Cell LungSolid Tumors

Phase 1

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

CompletedNCT02324257

Hoffmann-La RocheSolid Tumors

Start: 2014-12-30End: 2019-09-03Updated: 2020-04-17

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

CompletedNCT02650713

Hoffmann-La RocheSolid Tumors

Start: 2016-01-07End: 2020-01-13Updated: 2020-02-12

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

CompletedNCT03337698

Hoffmann-La RocheCarcinoma, Non-Small-Cell Lung

Start: 2017-12-27End: 2025-11-25Updated: 2025-12-12

Related Papers

Abstract 1047: MORPHEUS-lung: Biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer

Cancer Research2026-04-03

Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial

Cancer2025-05-141 citations

Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure

Frontiers in Immunology2024-05-316 citations

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.

2024-05-1528 citations

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)

JNCI Journal of the National Cancer Institute2024-05-069 citations

Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer

Chinese Medical Journal2020-09-15

Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)

Cancer Research2020-08-154 citations

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Annals of Oncology2018-10-0119 citations

MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2018-05-2011 citations

Abstract 1594: Enhancement of the anti-tumor activity of CEA TCB via combination with checkpoint blockade by PD-L1 and interleukin-2 variant immunocytokine

Cancer Research2017-07-01

Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2017-05-20164 citations

Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB

Journal of Immunotherapy2016-07-1439 citations

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

2016-02-09263 citations